Marlborough development-stage pharmaceutical company Advanced Cell Technology swung to a $4.8-million second-quarter loss, compared to a $2.9-million profit last year.
Revenues for the company – which are gained from license fees and royalty payments – decreased from $205,000 last year to $153,000 this year.
The company also almost doubled its cash used as it prepared for Phase I and Phase II clinical trials on two of its eye-related therapies.
